These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Beneficial effects of cytokine induced hyperlipidemia. Feingold KR; Hardardóttir I; Grunfeld C Z Ernahrungswiss; 1998; 37 Suppl 1():66-74. PubMed ID: 9558731 [TBL] [Abstract][Full Text] [Related]
3. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Ripollés Piquer B; Nazih H; Bourreille A; Segain JP; Huvelin JM; Galmiche JP; Bard JM Metabolism; 2006 Jul; 55(7):980-8. PubMed ID: 16784973 [TBL] [Abstract][Full Text] [Related]
4. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Noto H; Hara M; Karasawa K; Iso-O N; Satoh H; Togo M; Hashimoto Y; Yamada Y; Kosaka T; Kawamura M; Kimura S; Tsukamoto K Arterioscler Thromb Vasc Biol; 2003 May; 23(5):829-35. PubMed ID: 12649088 [TBL] [Abstract][Full Text] [Related]
5. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. de Vries R; Borggreve SE; Dullaart RP Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331 [TBL] [Abstract][Full Text] [Related]
6. Lipid and lipoprotein metabolism in chronic kidney disease. Kaysen GA J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776 [TBL] [Abstract][Full Text] [Related]
8. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Mertens A; Verhamme P; Bielicki JK; Phillips MC; Quarck R; Verreth W; Stengel D; Ninio E; Navab M; Mackness B; Mackness M; Holvoet P Circulation; 2003 Apr; 107(12):1640-6. PubMed ID: 12668499 [TBL] [Abstract][Full Text] [Related]
9. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Brites FD; Verona J; Schreier LE; Fruchart JC; Castro GR; Wikinski RL Arch Med Res; 2004; 35(3):235-40. PubMed ID: 15163466 [TBL] [Abstract][Full Text] [Related]
10. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641 [TBL] [Abstract][Full Text] [Related]
11. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia. Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122 [TBL] [Abstract][Full Text] [Related]
12. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147 [TBL] [Abstract][Full Text] [Related]
13. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Kontush A; Chapman MJ Pharmacol Rev; 2006 Sep; 58(3):342-74. PubMed ID: 16968945 [TBL] [Abstract][Full Text] [Related]
14. Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Dallinga-Thie GM; Dullaart RP; van Tol A Curr Opin Lipidol; 2007 Jun; 18(3):251-7. PubMed ID: 17495597 [TBL] [Abstract][Full Text] [Related]
15. Effects of short-term and long-term danazol treatment on lipoproteins, coagulation, and progression of atherosclerosis: two clinical trials in healthy volunteers and patients with hereditary angioedema. Birjmohun RS; Kees Hovingh G; Stroes ES; Hofstra JJ; Dallinga-Thie GM; Meijers JC; Kastelein JJ; Levi M Clin Ther; 2008 Dec; 30(12):2314-23. PubMed ID: 19167590 [TBL] [Abstract][Full Text] [Related]
16. The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol. Nicholls S; Lundman P Semin Vasc Med; 2004 May; 4(2):187-95. PubMed ID: 15478040 [TBL] [Abstract][Full Text] [Related]
17. A Caucasian male with very low blood cholesterol and low apoA-II without evidence of atherosclerosis. Park SH; Kim JR; Park JE; Cho KH Eur J Clin Invest; 2007 Apr; 37(4):249-56. PubMed ID: 17373959 [TBL] [Abstract][Full Text] [Related]